Eli Lilly and Company (NYSE: LLY) announced it will present data from its Phase 3 EMBER-3 trial for imlunestrant, an oral selective estrogen receptor degrader (SERD), at the San Antonio Breast Cancer Symposium (SABCS) from December 10-13. This late-breaking presentation marks the first time EMBER-3 data will be publicly shared. EMBER-3 is evaluating imlunestrant as […]
Eli Lilly and Company has committed $4.5 billion to establish a revolutionary facility in Lebanon, Indiana—the Lilly Medicine Foundry. This one-of-a-kind site is set to transform how medicines are developed and produced for clinical trials, accelerating the delivery of life-saving therapies to patients worldwide. The investment is part of Lilly’s broader strategy to expand its […]
Eli Lilly and Company (NYSE: LLY) announced results from its QWINT-5 phase 3 trial, demonstrating that its once-weekly insulin efsitora alfa offers a comparable reduction in A1C levels to daily insulin degludec for adults with type 1 diabetes. This data, published in The Lancet and presented at the European Association for the Study of Diabetes […]
Organon and Eli Lilly and Company have expanded their commercialization agreement for Emgality, a leading migraine treatment, into 11 additional markets, reinforcing their commitment to addressing one of the most prevalent neurological disorders worldwide. Organon and Eli Lilly Expand Emgality Agreement Organon, a global healthcare company with a focus on women’s health, and Eli Lilly […]
Eli Lilly and Company (NYSE: LLY) has released compelling results from the SURMOUNT-1 study, which highlights that tirzepatide (branded as Zepbound and Mounjaro) dramatically cuts the risk of developing type 2 diabetes by an astounding 94% in adults suffering from pre-diabetes and obesity or overweight. This significant three-year study not only underscores the drug’s potential […]
Eli Lilly and Company (NYSE: LLY) has entered into a partnership with OpenAI to harness generative AI for the discovery of new antimicrobials, aiming to tackle the critical issue of antimicrobial resistance (AMR). This initiative marks a significant advancement in the pharmaceutical industry’s efforts against one of the most daunting health challenges today. Antimicrobial resistance […]
In a historic move for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has announced a staggering $5.3 billion expansion of its Lebanon, Indiana manufacturing site. This investment increases the total commitment to this site to $9 billion, aimed at boosting the production of active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro […]
In a significant advancement for medical science and hearing loss treatment, Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), has unveiled encouraging initial clinical results from its Phase 1/2 AK-OTOF-101 study. This groundbreaking research, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, marks […]
Eli Lilly and Company (NYSE: LLY) has announced the successful completion of its $1.4 billion acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a notable radiopharmaceutical company. This acquisition, worth $12.5 per share in cash, marks a significant step in Eli Lilly’s expansion in cancer treatment solutions. Advancing Cancer Treatments The acquisition brings together POINT’s […]
In a strategic move to strengthen its position in the life sciences sector, Eli Lilly and Company (NYSE: LLY) has revealed plans to inaugurate its first-ever Lilly Gateway Labs facility in San Diego, California, in the first half of 2024. This initiative marks the company’s third such facility, joining its existing sites in San Francisco […]